Case of iatrogenic botulism after botulinotherapy in clinical practice


Cite item

Full Text

Abstract

Injections of botulinum toxin are widely used in different medical fields, namely neurology, urology, stomatology, cosmetology, gastroenterology etc. Preparations of botulinum toxin type A (BTA) prevent the release of acetylcholine at the endings of motor nerves leading to the long-term muscle relaxation. It has been acknowledged that treatment with BTA has very good safety profile and tolerability. Extremely rare but severe complication of botulinotherapy (BT) is a condition, which is associated with generalized muscle Weakness, swallowing difficulty, respiratory arrest, and may lead to the lethal outcomes in the solitary cases. Such disorders, which present like botulism, are known as botulism-like syndrome and iatrogenic botulism. We report a clinical case of such complication in the paper. The probability of the development of such rare but severe complications necessitates certain awareness and vigilance among clinicians performing BT.

About the authors

R A Ibatullin

Bashkir State Medical University; G.G. Kuvatov Republican Clinical Hospital

Author for correspondence.
Email: robib@ufanet.ru

к.м.н., доцент каф. неврологии с курсами нейрохирургии и медицинской генетики ФГБОУ ВО «Башкирский государственный медицинский университет»

Ufa, Bashkortostan, Russia

R V Magjanov

Bashkir State Medical University; G.G. Kuvatov Republican Clinical Hospital

Email: fake@conmed.ru

проф. каф. неврологии с курсами нейрохирургии и медицинской генетики ФГБОУ ВО «Башкирский государственный медицинский университет»

Ufa, Bashkortostan, Russia

References

  1. Girlanda P, Vita G, Nicolosi C, Milone S, Messina C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurology, Neurosurgery & Psychiatry. 1992;55(9): 844-5. doi: 10.1136/jnnp.55.9.844
  2. Tugnoli V, Eleopra R, Montecucco C, De Grandis D. The therapeutic use of botulinum toxin. Expert Opinion on Investigational Drugs. 1997;6(10):1383-94. doi: 10.1517/13543784.6.10.1383
  3. Brodsky M.A, Swope D.M, Grimes D, Diffusion of Botulinum Toxins. Tremor Other Hyperkinet Mov (NY). 2012;2:tre-02-85-417-1. doi: 10.7916/D88W3C1M
  4. Coban A, Matur Z, Hanagasi H.A, Parman Y. Iatrogenic Botulism After Botulinum Toxin Type A Injections. Clin Neuropharmacol. 2010;33(3):158-60. doi: 10.1097/wnf.0b013e3181d479e0
  5. Bakheit A.M, Ward C.D, Mc Lellan D.L. Generalised botulism - like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurology, Neurosurgery & Psychiatry. 1997; 62(2):198. doi: 10.1136/jnnp.62.2.198
  6. Bhatia K.P, Munchau A, Thompson P.D, Houser M, Chauhan V.S, Hutchinson M, Marsden C.D. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurology, Neurosurgery & Psychiatry. 1999;67(1):90-3. doi: 10.1136/jnnp.67.1.90
  7. US Food and Drug Administration. Botox and Botox Cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B) 2009 [cited 2011 December 29]; Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm164255.htm. Accessed February 6, 2017.
  8. Cobb D.B, Watson W.A, Fernandez M.C. Botulism - like syndrome after injections of botulinum toxin. Vet Hum Toxicol. 2000 Jun;42:163.
  9. Nong L.B, He W.Q, Xu Y.H, Liu X.Q, Li Y.M, Xiao Z.L, Zhong N.S. Severe respiratory failure after injection of botulinum toxin: case report and review of the literature. Zhonghua Jie He He Hu Xi Za Zhi. 2008 May; 31(5):369-71.
  10. Fan K.L, Wang Y.L, Chu G, Leung L.P. Delayed Antitoxin Treatment of Two Adult Patients with Botulism after Cosmetic Injection of Botulinum Type A Toxin. J Emergency Med. 2016;51(6):677-9. doi: 10.1016/j.jemermed.2016.07.097
  11. Ghasemi M, Norouzi R, Salari M, Asadi B. Iatrogenic Botulism After the Therapeutic Use of Botulinum Toxin-A. Clin Neuropharmacol. 2012;35(5):254-7. doi: 10.1097/wnf.0b013e31826248b8
  12. Omprakash H, Rajendran S. Botulinum toxin deaths: What is the fact? J Cutaneous and Aesthetic Surgery. 2008;1(2):95. doi: 10.4103/0974-2077.44169
  13. Erbguth F, Claus D, Engelhardt A, Dressler D. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurology, Neurosurgery & Psychiatry. 1993; 56(11):1235-6. doi: 10.1136/jnnp.56.11.1235
  14. Barclay L. Respiratory compromise, death may be linked to botulinum toxin. Medical alerts. 2008 (Febr 8); Available at: http://www.medscape.com. Accessed February 11, 2017
  15. Beseler-Soto B, Sánchez-Palomares M, Benlloch-Muncharaz M, Santos-Serrano L, Landa-Rivera L, Ferriol-Camacho M, Paricio-Talayero J.M. Efectos adversos de la toxina botulínica en el tratamiento de la espasticidad infantil. Rev Neurol. 2007;45:318-19.
  16. Goldstein E.M. Safety of high - dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol. 2006;21:189-92. doi: 10.2310/7010.2006.00041
  17. Beseler-Soto B, Sánchez-Palomares M, Santos-Serrano L, Landa-Rivera L, Sanantonio-Valdearcos F, Paricio-Talayero J.M. Botulismo yatrógeno: una complicación a tener en cuenta en el tratamiento de la espasticidad en la infancia. Rev Neurol. 2003;37:444-6.
  18. Howell K, Selber P, Graham H.K, Reddihough D. Botulinum neurotoxin A: An unusual systemic effect. J Paediatrics and Child Health. 2007; 43(6):499-501. doi: 10.1111/j.1440-1754.2007.01122.x
  19. Naidu K, Smith K, Sheedy M, Adair B, Yu X, Graham H.K. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Developmental Medicine & Child Neurology. 2010;52(2): 139-44. doi: 10.1111/j.1469-8749.2009.03583.x
  20. Jankovic J, Schwartz K.S. Clinical Correlates of Response to Botulinum Toxin Injections. Archives of Neurol. 1991;48(12):1253-6. doi: 10.1001/archneur.1991.00530240057020
  21. Blaszczyk I, Foumani N, Ljungberg C, Wiberg M. Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy. Toxins. 2015;7(11):4645-54. doi: 10.3390/toxins7114645

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies